We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Akero Therapeutics, Inc. (AKRO) Outperforming Other Medical Stocks This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Akero Therapeutics, Inc. (AKRO - Free Report) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Akero Therapeutics, Inc. is one of 1160 individual stocks in the Medical sector. Collectively, these companies sit at #9 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Akero Therapeutics, Inc. is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for AKRO's full-year earnings has moved 12.3% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Our latest available data shows that AKRO has returned about 2.3% since the start of the calendar year. At the same time, Medical stocks have lost an average of 6%. As we can see, Akero Therapeutics, Inc. is performing better than its sector in the calendar year.
Another stock in the Medical sector, Butterfly Network, Inc. (BFLY - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 1.6%.
Over the past three months, Butterfly Network, Inc.'s consensus EPS estimate for the current year has increased 28.8%. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, Akero Therapeutics, Inc. is a member of the Medical - Biomedical and Genetics industry, which includes 538 individual companies and currently sits at #162 in the Zacks Industry Rank. On average, this group has lost an average of 8.7% so far this year, meaning that AKRO is performing better in terms of year-to-date returns.
Butterfly Network, Inc. however, belongs to the Medical Info Systems industry. Currently, this 47-stock industry is ranked #172. The industry has moved -10.5% so far this year.
Investors with an interest in Medical stocks should continue to track Akero Therapeutics, Inc. and Butterfly Network, Inc. These stocks will be looking to continue their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Akero Therapeutics, Inc. (AKRO) Outperforming Other Medical Stocks This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Akero Therapeutics, Inc. (AKRO - Free Report) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Akero Therapeutics, Inc. is one of 1160 individual stocks in the Medical sector. Collectively, these companies sit at #9 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Akero Therapeutics, Inc. is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for AKRO's full-year earnings has moved 12.3% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Our latest available data shows that AKRO has returned about 2.3% since the start of the calendar year. At the same time, Medical stocks have lost an average of 6%. As we can see, Akero Therapeutics, Inc. is performing better than its sector in the calendar year.
Another stock in the Medical sector, Butterfly Network, Inc. (BFLY - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 1.6%.
Over the past three months, Butterfly Network, Inc.'s consensus EPS estimate for the current year has increased 28.8%. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, Akero Therapeutics, Inc. is a member of the Medical - Biomedical and Genetics industry, which includes 538 individual companies and currently sits at #162 in the Zacks Industry Rank. On average, this group has lost an average of 8.7% so far this year, meaning that AKRO is performing better in terms of year-to-date returns.
Butterfly Network, Inc. however, belongs to the Medical Info Systems industry. Currently, this 47-stock industry is ranked #172. The industry has moved -10.5% so far this year.
Investors with an interest in Medical stocks should continue to track Akero Therapeutics, Inc. and Butterfly Network, Inc. These stocks will be looking to continue their solid performance.